Satsuma Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder f…

Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Satsuma Pharmaceuticals, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Satsuma Pharmaceuticals, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Satsuma Pharmaceuticals, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of STSA's Analysis
CIK: 1692830 CUSIP: 80405P107 ISIN: US80405P1075 LEI: - UEI: -
Secondary Listings
STSA has no secondary listings inside our databases.